Skip to main content
Journal cover image

Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.

Publication ,  Journal Article
Shikuma, CM; Le, T; Phuong, TV; Chew, GM; Nguyen, VVC; Vo, TL; Siriwardhana, C; Chow, D; Ghukasyan, H; Limpruttidham, N; Premeaux, T; Paul, R ...
Published in: AIDS Res Hum Retroviruses
June 2022

The impact of HIV antiretroviral therapy (ART) on immune dysregulation associated with hepatitis C virus (HCV)/HIV coinfection is incompletely understood. We serially assessed monocyte activation (neopterin, sCD14, and sCD163) and T cell activation (HLA-DR, CD38) and immune exhaustion [program cell death protein 1 (PD1), TIGIT] in HIV/HCV-coinfected individuals who participated in a randomized trial performed in Vietnam designed to assess the hepatotoxicity of raltegravir (RAL)- versus efavirenz (EFV)-based therapy when used as first-time ART in combination with tenofovir disoproxil fumarate and emtricitabine. Baseline pre-ART values were compared with those from ART-naive HIV-monoinfected and HIV-seronegative individuals. Before ART, HIV/HCV-coinfected individuals had higher levels of neopterin, sCD14, and sCD163, and increased frequencies of CD38+HLA-DR+, PD1+, and TIGIT+ CD4 and CD8 T cells compared with ART-naive HIV-monoinfected or HIV-seronegative individuals (all p < .01). Most parameters did not normalize despite 72 weeks of ART. In particular sCD163 persisted at high levels. Improvement over 72 weeks in fibrosis as assessed by FibroScan® correlated with reductions in plasma sCD163 and in the frequencies of T cell activation, single PD1+, TIGIT+, and dual PD1+TIGIT+ CD8 T cells. A nonsignificant tendency toward more favorable effects on monocyte and T cell immune activation and on T cell exhaustion were seen with RAL-compared with EFV-based therapy. The initiation of ART in HIV/HCV-coinfected individuals is associated with incomplete improvement in monocyte and T cell immune activation and exhaustion, which was associated with some corresponding improvement in liver fibrosis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

AIDS Res Hum Retroviruses

DOI

EISSN

1931-8405

Publication Date

June 2022

Volume

38

Issue

6

Start / End Page

441 / 450

Location

United States

Related Subject Headings

  • Virology
  • Vietnam
  • Raltegravir Potassium
  • Neopterin
  • Lipopolysaccharide Receptors
  • Humans
  • Hepatitis C
  • Hepacivirus
  • HLA-DR Antigens
  • HIV Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shikuma, C. M., Le, T., Phuong, T. V., Chew, G. M., Nguyen, V. V. C., Vo, T. L., … Ndhlovu, L. C. (2022). Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. AIDS Res Hum Retroviruses, 38(6), 441–450. https://doi.org/10.1089/AID.2021.0076
Shikuma, Cecilia M., Thuy Le, Thao Vu Phuong, Glen M. Chew, Van Vinh Chau Nguyen, Trieu Ly Vo, Chathura Siriwardhana, et al. “Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.AIDS Res Hum Retroviruses 38, no. 6 (June 2022): 441–50. https://doi.org/10.1089/AID.2021.0076.
Shikuma CM, Le T, Phuong TV, Chew GM, Nguyen VVC, Vo TL, et al. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. AIDS Res Hum Retroviruses. 2022 Jun;38(6):441–50.
Shikuma, Cecilia M., et al. “Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.AIDS Res Hum Retroviruses, vol. 38, no. 6, June 2022, pp. 441–50. Pubmed, doi:10.1089/AID.2021.0076.
Shikuma CM, Le T, Phuong TV, Chew GM, Nguyen VVC, Vo TL, Siriwardhana C, Chow D, Ghukasyan H, Limpruttidham N, Premeaux T, Gangcuangco LM, Paul R, Ndhlovu LC. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. AIDS Res Hum Retroviruses. 2022 Jun;38(6):441–450.
Journal cover image

Published In

AIDS Res Hum Retroviruses

DOI

EISSN

1931-8405

Publication Date

June 2022

Volume

38

Issue

6

Start / End Page

441 / 450

Location

United States

Related Subject Headings

  • Virology
  • Vietnam
  • Raltegravir Potassium
  • Neopterin
  • Lipopolysaccharide Receptors
  • Humans
  • Hepatitis C
  • Hepacivirus
  • HLA-DR Antigens
  • HIV Infections